Close Menu

North America

With at-home testing and online, patient-centered reports, the CureCloud initiative sets out to break down barriers to targeted treatment options while building a broad patient dataset.

The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.

The funding will be used to advance the firm's lead drug candidate, OP-1250, into a Phase I/II trial of ER-positive, HER2-negative breast cancer.  

The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging. 

GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.

The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.

An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.

The initiative will offer a liquid biopsy tool that only requires a blood draw for cancer treatment selection instead of a tissue biopsy. 

The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.

The analysis suggested CDK7 inhibitors could boost the sensitivity of tumor cells capable of homologous recombination to PARP inhibitor treatment.

Pages